Amyotrophic lateral sclerosis (ALS) is a rare neurogenerative disease, and organizations including the FDA and NIH are working to accelerate potential therapies. What’s on the horizon for the treatment landscape? Mario Nacinovich joins Dr. Walter Koroshetz, who is the Director of the National Institute of Neurological Disorders and Stroke, to explore these new developments.